Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Схожі ресурси

• Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
  за авторством: Qian Jiang, та інші
  Опубліковано: (2022-10-01)
• Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
  за авторством: Qian Jiang, та інші
  Опубліковано: (2023-02-01)
• Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
  за авторством: Hengbang Wang, та інші
  Опубліковано: (2024-09-01)
• Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study
  за авторством: Ziyu Wen, та інші
  Опубліковано: (2025-05-01)
• A nomogram for predicting T315I-free survival in chronic phase chronic myeloid leukemia patients: a multicenter retrospective study
  за авторством: Shi-wei Hu, та інші
  Опубліковано: (2025-02-01)